Introduction {#s1}
============

The QT interval reflects electrical depolarization and repolarization of both ventricles. Rate-corrected QT (QTc) intervals are almost identical in males and females till late adolescence (0.37 - 0.44 s). After which, the normal range of QTc interval is slightly longer in females (\< 0.47s) than in males (\< 0.45s) \[[@R01]\].

Prolonged QT interval seen on electrocardiogram (EKG) is known as Long QT syndrome. This syndrome is often associated with increased risk of arrhythmias especially torsades de pointes (TdP), a distinctive form of polymorphic ventricular tachycardia characterized by changes in the amplitude and deformation of QRS complexes around the isoelectric line. TdP may potentially degenerate into ventricular fibrillation (VF) and cause sudden cardiac death (SCD), if not treated promptly.

Acquired forms of Long QT syndrome are usually provoked by the presence of extrinsic triggers such as QT-prolonging drugs, hypokalemia or hypomagnesemia, and bradycardia. However, the most common culprit is those associated with QT prolonging drugs which are still regularly being used in clinical practice, namely antihistamines, antibiotics, antidepressants, and prokinetics. In recent days, more and more drugs have started identifying QTc prolongation as their adverse effect. Nonetheless, these drugs are still being prescribed by clinicians probably because they are unaware of the relative risk of QTc prolongations and their impact on patients. There are plenty of case reports and systematic review based on case reports published on drug induced QTc prolongation. In this systematic review of research articles, we have focused on identifying the common drugs that have been known to prolong QTc and analyze their cardiac side effects and their impact on mortality.

Methods {#s2}
=======

This systematic review was performed according to the PRISMA guidelines \[[@R02]\].

Data sources and searches {#s2a}
-------------------------

Comprehensive search was conducted on PubMed and EMBASE databases by using the term ((drug induced QT syndrome) or (medication induced QT syndrome)) and ((outcome) or (adverse events)) for studies published until May 2, 2017. Two authors independently screened titles and abstracts to identify relevant studies in English and discrepancies were resolved by consensus. Duplicates were removed prior to study selection. Full texts of potentially relevant articles were assessed independently for eligibility by two authors. The search was supplemented by screening the studies included in similar systematic reviews and meta-analysis ([Fig. 1](#F1){ref-type="fig"}).

![Flowchart illustrates the process of including and excluding studies following PRISMA guidelines using PubMed and EMBASE database.](jocmr-10-384-g001){#F1}

Study selection {#s2b}
---------------

Inclusion criteria include: 1) studies analyzing QT prolongation due to medications, 2) more than 10 subjects, 3) studies that identify QT measurement or change in QTc, drug usage, measured outcomes and other cardiac side effects.

Exclusion criteria include: 1) age less than 18 years old, 2) patients with congenital long QT syndrome, 3) case reports, case series, review articles, 4) studies with less than 10 subjects, 5) studies that doesn't discuss outcomes, 6) articles in language other than English, 8) studies that reports only events without number of patients screened or affected, 9) studies using off market drugs and experimental drugs.

Outcomes of interest {#s2c}
--------------------

The primary outcome was to identify drugs causing QT prolongation compared to baseline. Secondary outcomes included their impact and other side effects observed among the patients taking these drugs namely, ventricular arrhythmias, TdP and death.

Results {#s3}
=======

Out of 176 non-duplicate reports, 36 studies satisfied inclusion criteria and provided data on patients exposed to drugs that can potentially cause long QT.

Geographically, 12/36 studies were done in USA, multicenter studies account for 11/36 studies, one study was done in UK/France/Germany/Turkey/Greece/Taiwan/Iran, two studies were done in Switzerland. Study design distributions were: cross sectional studies in 3/36, prospective observational in 3/36, retrospective studies in 10/36 and randomized controlled trials in 19/36 ([Table 1](#T1){ref-type="table"}, \[[@R03]-[@R38]\]).

###### Summary of Studies With Age, Type of Study, Gender, Drugs Used and Distribution of QTc Prolongation

  Author                           Country       Year/ study period   Type of study               Age             M       F       N~T~     N~1~    N~2~   N~c~   Drug1                                                                       Drug2            Poly pills                                                                                                 Major diagnosis/ indication                             Total QTc prolongation
  -------------------------------- ------------- -------------------- --------------------------- --------------- ------- ------- -------- ------- ------ ------ --------------------------------------------------------------------------- ---------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------
  Agusala et al \[[@R03]\]         USA           n/a                  Retrospective               63 ± 13         231     98      329      227     102    n/a    Sotalol                                                                     Dofetilide       n/a                                                                                                        Atrial fibrillation                                     55
  Armahizer et al \[[@R04]\]       USA           2009                 Retrospective               62 ± 15.2       102     85      501      n/a     n/a    n/a    n/a                                                                         n/a              Ondansetron, amiodarone, metronidazole and haloperidol                                                     Drug-drug interaction in CCU/CTICU                      187
  Cunnington et al \[[@R05]\]      UK            2012                 Retrospective               76.5            75      37      112      61      n/a    n/a    n/a                                                                         n/a              Domperidone, citalopram, amitriptyline, hydroxychloroquine, quetiapine, mirtazapine, quinine, olanzapine   Parkinson's disease                                     20
  Hough et al \[[@R06]\]           USA           02/2006 - 06/2006    Randomized prospective      37 (18 - 51)    78      31      109      44      43     22     Paliperidone ER                                                             Quetiapine       n/a                                                                                                        Schizophrenia and schizoaffective dis                   n/a
  Letsas et al \[[@R07]\]          Greece        02/2004 - 10/2006    Retrospective               64.3 ± 14.1     2       19      21       n/a     n/a    n/a    n/a                                                                         n/a              Amiodarone, sotalol, digoxin, indapamide                                                                   Multiple                                                n/a
  Moffett et al \[[@R08]\]         USA           2012 - 2013          Prospective observational   32 ± 5          9       13      22       22      n/a    n/a    Ondansetron                                                                 n/a              n/a                                                                                                        Nausea, vomiting                                        20
  Niedrig et al \[[@R9]\]          Switzerland   2012                 Retrospective               n/a             n/a     n/a     51       n/a     n/a    n/a    Macrolide and quinolone antibiotics (MQABs) with \> 1 QT prolonging drugs   n/a              Y                                                                                                          Bacterial infection requiring systemic MQ antibiotics   n/a
  Perrin-Terrin et al \[[@R10]\]   France                             Retrospective               34 ± 8          37      5       42       42      n/a    n/a    Methadone                                                                   n/a              n/a                                                                                                        Heroin addiction                                        n/a
  Potkin et al \[[@R11]\]          USA           2001 - 2002          Randomized prospective      n/a             n/a     n/a     188      113     35     35     Iloperidone (8,12,24mg)                                                     Quetiapine       n/a                                                                                                        Schizophrenia and schizoaffective dis                   10
  Wieneke et al \[[@R12]\]         Germany       24 weeks             Randomized prospective      29.5            30      23      53       31      22     n/a    Levo-α-Acetylmethadol (LAAM)                                                Methadone        n/a                                                                                                        Opiate addiction                                        7
  Beyraghi et al \[[@R13]\]        Iran          01/2010 - 06/2010    Cross-sectional             35.3            27      47      74       n/a     n/a    n/a    n/a                                                                         n/a              Antipsychotics, anticholinergic, antidepressant, lithium, other mood stabilizer                            Bipolar, schizo, MDD, others                            22
  Koca et al \[[@R14]\]            Turkey        2009 - 2010          Prospective observational   59              13      39      52       52      0      0      Capecitabine                                                                n/a              n/a                                                                                                        Malignancy                                              10
  Lee et al \[[@R15]\]             USA           n/a                  Retrospective               55 ± 19.5       39      61      100      n/a     n/a    n/a    Azithromycin                                                                n/a              DDI = ondansetron (48%), trazodone (22%), and moxifloxacin (17%)                                           Hospitalized respiratory/gynae infections               29
  Pearson et al \[[@R16]\]         USA           2 years              Retrospective               46 ± 11         23      35      59       n/a     n/a    n/a    Methadone                                                                   n/a              n/a                                                                                                        Opiate addiction                                        16
  Price et al \[[@R17]\]           USA           1969 - 2002          Retrospective               55.9            481     765     1,246    633     613    n/a    Methadone                                                                   n/a              n/a                                                                                                        Pain management                                         249
  Van der Sijs et al \[[@R18]\]    Netherlands   2010                 Retrospective               n/a             32      24      56       n/a     n/a    n/a    n/a                                                                         n/a              Haloperidol, amiodarone, sotalol etc.                                                                      Multiple                                                25
  Azorin et al \[[@R19]\]          Multicenter   2006                 Randomized prospective      n/a             n/a     n/a     186      97      89     n/a    Sertindole                                                                  Risperidone      n/a                                                                                                        Schizophrenia                                           26
  Chan et al \[[@R20]\]            Taiwan                             Randomized prospective      35              45      38      83       49      34     n/a    Aripiprazole                                                                Risperidone      n/a                                                                                                        Schizophrenia                                           n/a
  Beasley et al \[[@R21]\]         Multicenter   2004 - 2005          Randomized prospective      36 ± 10         294     41      335      198     69     68     Olanzapine                                                                  Haloperidol      n/a                                                                                                        Schizophrenia                                           n/a
  Conley et al \[[@R22]\]          Multicenter                        Randomized prospective      40 ± 10.8       274     103     377      188     189    n/a    Risperidone                                                                 Olanzapine       n/a                                                                                                        Schizophrenia                                           n/a
  Feischhacker et al \[[@R23]\]    Multicenter                        Randomized prospective      36.6            399     296     695      350     345    n/a    Aripiprazole                                                                Olanzapine       n/a                                                                                                        Schizophrenia                                           12
  Kane et al \[[@R24]\]            USA           2000 - 2002          Randomized prospective      38.6 ± 0.5      288     126     414      206     104    106    Aripiprazole                                                                Haloperidol      n/a                                                                                                        Schizophrenia                                           4
  Kane et al \[[@R25]\]            USA           1997 - 1998          Randomized prospective      35 ± 8.85       n/a     n/a     306      152     154    n/a    Ziprasidone                                                                 Chlorpromazine   n/a                                                                                                        Schizophrenia                                           n/a
  McEvoy et al \[[@R26]\]          USA                                Randomized prospective      40.4 ± 0.5      326     94      420      312     n/a    108    Aripiprazole                                                                n/a              n/a                                                                                                        Schizophrenia                                           3
  Min et al \[[@R27]\]             South Korea                        Randomized prospective      23.5            n/a     n/a     35       16      19     n/a    Risperidone                                                                 Haloperidol      n/a                                                                                                        Schizophrenia                                           n/a
  Peuskens et al \[[@R28]\]        Multicenter                        Randomized prospective      38.1            n/a     n/a     1,362    1,136   226    n/a    Risperidone                                                                 Haloperidol      n/a                                                                                                        Schizophrenia                                           n/a
  Peuskens et al \[[@R29]\]        Multicenter                        Randomized prospective      36.5            120     108     228      115     113    n/a    Amisulpride                                                                 Risperidone      n/a                                                                                                        Schizophrenia                                           4
  Potkin et al \[[@R30]\]          Multicenter   1995 - 1996          Randomized prospective      39.1            283     121     404      202     99     103    Aripiprazole                                                                Risperidone      n/a                                                                                                        Schizophrenia                                           3
  Sacchetti et al \[[@R31]\]       Multicenter                        Randomized prospective      39.95 ± 10.7    101     45      146      73      73     n/a    Ziprasidone                                                                 Clozapine        n/a                                                                                                        Schizophrenia                                           13
  Tran et al \[[@R32]\]            Multicenter                        Randomized prospective      36.21 ± 10.73   220     119     339      172     167    n/a    Olanzapine                                                                  Risperidone      n/a                                                                                                        Schizophrenia                                           23
  Vieta et al \[[@R33]\]           Multicenter                        Randomized prospective      n/a             127     207     334      175     169    n/a    Aripiprazole                                                                Haloperidol      ddI = ondansetron (48%), trazodone (22%), and moxifloxacin (17%)                                           Mania                                                   9
  Haixu et al \[[@R34]\]           China         52 weeks             Cross-sectional             66.6 ± 14.4     1,731   2,390   4,121    n/a     n/a    n/a    n/a                                                                         n/a              Multiple                                                                                                   Acquired long QT syndrome in hospitalized pts           106
  Niedrig et al \[[@R35]\]         Switzerland   21 days              Cross-sectional             n/a             n/a     n/a     243      186     n/a    57     Citalopram+escitalopram                                                     n/a              n/a                                                                                                        Major depression                                        15
  Van Haelst et al \[[@R36]\]      Netherlands   2007 - 2012          Cross-sectional             70 ± 7          154     243     397      n/a     n/a    n/a    SSRI's                                                                      n/a              Multiple                                                                                                   Major depression                                        44
  Manini et al \[[@R37]\]          USA           2012 - 2013          Prospective observational   42.3 ± 0.8      255     217     472      n/a     n/a    n/a    n/a                                                                         n/a              Methadone, oxycodone, other opiods, benzodiazepines etc.                                                   Acute drug overdose                                     60
  Kasper et al \[[@R38]\]          Multicenter   12 weeks             Randomized prospective      37.1 ± 10.3     758     536     1,241    810     431    n/a    Aripiprazole                                                                Haloperidol      n/a                                                                                                        Schizophrenia                                           2
  Total                                                                                           43.8            6,554   5,966   15,153                                                                                                                                                                                                                                                                                         974

M: male; F: female; n/a: unavailability of data; N~T~: total number of patients in the study; N~1~: number of patients exposed to drug 1; N~2~: number of patients exposed to drug 2; N~c~: number of patients exposed to control drug; DDI: drug-drug interactions.

Drugs used in studying QTc prolongation were distributed as follows out of 36 studies: multiple drugs in 10/36 studies, haloperidol in 6/36 studies, olanzapine, ziprasidone and quetiapine in 2/36, risperidone in 5/36, methadone in 4/36, aripiprazole in 7/36, Other drugs (clozapine/chlorpromazine/dofetilide/capecitabine/azithromycin/amisulpride/ citalopram/ escitalopram/sotalol/paliperidone ER/ondansetron/fluoroquinolone antibiotics/azithromycin/sertindole/LAAM/iloperidone) one each out of 36 studies. Multiple drugs is designated as a variable when a study uses more than two drugs in the study population or more than two drugs in the same patient.

Totally, 14,756 patients were exposed and 930 patients (6.3%) were found to have QTc prolongation. Males were 6,400, females were 5,723 patients and mean age of the patients was 43.8 ± 9.36 ([Table 1](#T1){ref-type="table"}). Ventricular arrhythmias were found in 379 patients (2.6%), 26 patients were found to have PACs and PVCs. TdP was found in 49 patients (0.33 %), SCD was found in five patients and 586 were found to have all-cause mortality. Only two studies reported ventricular arrhythmias \[[@R03], [@R36]\]; two studies reported TdP \[[@R9], [@R19]\]; one study reported SCD \[[@R9]\]; and four studies reported death \[[@R18]-[@R20], [@R36]\]. Remaining studies either didn't report ventricular arrhythmias or didn't have any episodes of ventricular arrhythmias. In one of the studies using methadone, 43 out of 59 patients were found to have TdP \[[@R19]\], remaining six patients who had TdP were result of using multiple drugs \[[@R9]\]. The study is based on 5,503 reported adverse events from MedWatch database ([Table 2](#T2){ref-type="table"}, \[[@R03]-[@R38]\]).

###### Summary of Distribution of Different Types of Arrhythmias Among Qatients With QT Prolonging Drugs

  Author                           Drug1                                                                       Drug2            Poly pills                                                                                                 Total Qtc prolongation   Mean change in QTc                             Ventricular tachycardia   PVC/NSVT/ECTOPY   TdP   SCD/cardiac arrest   Death
  -------------------------------- --------------------------------------------------------------------------- ---------------- ---------------------------------------------------------------------------------------------------------- ------------------------ ---------------------------------------------- ------------------------- ----------------- ----- -------------------- -------
  Agusala et al \[[@R03]\]         Sotalol                                                                     Dofetilide       n/a                                                                                                        55                       n/a                                            70                        23                0     0                    0
  Armahizer et al \[[@R04]\]       n/a                                                                         n/a              Ondansetron, amiodarone, metronidazole and haloperidol                                                     187                      n/a                                            n/a                       n/a               0     n/a                  n/a
  Cunnington et al \[[@R05]\]      n/a                                                                         n/a              Domperidone, citalopram, amitriptyline, hydroxychloroquine, quetiapine, Mirtazapine, quinine, olanzapine   20                       n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Hough et al \[[@R06]\]           Paliperidone ER                                                             Quetiapine       n/a                                                                                                        n/a                      n/a                                            0                         0                 0     n/a                  0
  Letsas et al \[[@R07]\]          n/a                                                                         n/a              Amiodarone, sotalol, digoxin, indapamide                                                                   n/a                      n/a                                            0                         0                 6     5                    0
  Moffett et al \[[@R08]\]         Ondansetron                                                                 n/a              n/a                                                                                                        20                       n/a                                            0                         0                 0     0                    0
  Niedrig et al \[[@R9]\]          Macrolide and quinolone antibiotics (MQABs) with \> 1 QT prolonging drugs   n/a              Y                                                                                                          n/a                      n/a                                            0                         0                 0     n/a                  0
  Perrin-Terrin et al \[[@R10]\]   Methadone                                                                   n/a              n/a                                                                                                        n/a                      66.0 ± 41.1                                    0                         0                 0     0                    0
  Potkin et al \[[@R11]\]          Iloperidone (8,12,24mg)                                                     Quetiapine       n/a                                                                                                        10                       16.97 ± 14.13                                  0                         SVT = 1           0     0                    0
  Wieneke et al \[[@R12]\]         Levo-α-Acetylmethadol (LAAM)                                                Methadone        n/a                                                                                                        7                        40 ± 13                                        0                         0                 0     n/a                  0
  Beyraghi et al \[[@R13]\]        n/a                                                                         n/a              Antipsychotics, anticholinergic, antidepressant, lithium, other mood stabilizer                            22                       n/a                                            0                         0                 0     0                    0
  Koca et al \[[@R14]\]            Capecitabine                                                                n/a                                                                                                                         10                       n/a                                            n/a                       2                 n/a   n/a                  n/a
  Lee et al \[[@R15]\]             Azithromycin                                                                n/a              DDI = ondansetron (48%), trazodone (22%), and moxifloxacin (17%)                                           29                       n/a                                            n/a                       n/a               n/a   n/a                  4
  Pearson et al \[[@R16]\]         Methadone                                                                   n/a              n/a                                                                                                        16                       n/a                                            n/a                       n/a               43    n/a                  5
  Price et al \[[@R17]\]           Methadone                                                                   n/a              n/a                                                                                                        249                      n/a                                            n/a                       n/a               n/a   n/a                  42
  Van der Sijs et al \[[@R18]\]    n/a                                                                         n/a              Haloperidol, amiodarone, sotalol etc.                                                                      25                       59.76 ± 47.157                                 n/a                       n/a               n/a   n/a                  n/a
  Azorin et al \[[@R19]\]          Sertindole                                                                  Risperidone      n/a                                                                                                        26                       n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Chan et al \[[@R20]\]            Aripiprazole                                                                Risperidone      n/a                                                                                                        n/a                      (-1 ± 39, 8 ± 34)                              n/a                       n/a               n/a   n/a                  n/a
  Beasley et al \[[@R21]\]         Olanzapine                                                                  Haloperidol      n/a                                                                                                        n/a                      (-0.62 ± 24.57, 0.97 ± 26.07, -4.71 ± 18.75)   n/a                       n/a               n/a   n/a                  n/a
  Conley et al \[[@R22]\]          Risperidone                                                                 Olanzapine       n/a                                                                                                        n/a                      (-1.3 ± 25.7, 1.2 ± 20.2)                      n/a                       n/a               n/a   n/a                  n/a
  Feischhacker et al \[[@R23]\]    Aripiprazole                                                                Olanzapine       n/a                                                                                                        12                       n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Kane et al \[[@R24]\]            Aripiprazole                                                                Haloperidol      n/a                                                                                                        4                        n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Kane et al \[[@R25]\]            Ziprasidone                                                                 chlorpromazine   n/a                                                                                                        n/a                      12(7.5)                                        n/a                       n/a               n/a   n/a                  n/a
  McEvoy et al \[[@R26]\]          Aripiprazole                                                                n/a              n/a                                                                                                        3                        n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Min et al \[[@R27]\]             Risperidone                                                                 Haloperidol      n/a                                                                                                        n/a                      15.0 ± 22.2, 0.9 ± 33.0                        n/a                       n/a               n/a   n/a                  n/a
  Peuskens et al \[[@R28]\]        Risperidone                                                                 Haloperidol      n/a                                                                                                        n/a                      -1.71 ± 24.88, -4.1 ± 24                       n/a                       n/a               n/a   n/a                  n/a
  Peuskens et al \[[@R29]\]        Amisulpride                                                                 Risperidone      n/a                                                                                                        4                        n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Potkin et al \[[@R30]\]          Aripiprazole                                                                Risperidone      n/a                                                                                                        3                        -0.69 ± 22, 6.31 ± 29, -2.18 ± 21              n/a                       n/a               n/a   n/a                  n/a
  Sacchetti et al \[[@R31]\]       Ziprasidone                                                                 Clozapine        n/a                                                                                                        13                       6 ± 43.3,-3.6 ± 39.3                           n/a                       n/a               n/a   n/a                  n/a
  Tran et al \[[@R32]\]            Olanzapine                                                                  Risperidone      n/a                                                                                                        23                       -4.9 ± 44.9, 4.4 ± 35.1                        n/a                       n/a               n/a   n/a                  n/a
  Vieta et al \[[@R33]\]           Aripiprazole                                                                Haloperidol      ddI = ondansetron (48%), trazodone (22%), and moxifloxacin (17%)                                           9                        n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Haixu et al \[[@R34]\]           n/a                                                                         n/a              Multiple                                                                                                   106                      n/a                                            309                       n/a               n/a   n/a                  535
  Niedrig et al \[[@R35]\]         Citalopram + escitalopram                                                   n/a              n/a                                                                                                        15                       n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Van Haelst et al \[[@R36]\]      SSRIs                                                                       n/a              Multiple                                                                                                   44                       2.83                                           n/a                       n/a               n/a   n/a                  n/a
  Manini et al \[[@R37]\]          n/a                                                                         n/a              Methadone, oxycodone, other opiods, benzodiazepines etc.                                                   60                       n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Kasper et al \[[@R38]\]          Aripiprazole                                                                Haloperidol      n/a                                                                                                        2                        n/a                                            n/a                       n/a               n/a   n/a                  n/a
  Total                                                                                                                                                                                                                                    974                                                                     379                       26                49    5                    586

n/a: not available; PVC: premature ventricular contractions; NSVT: non sustained ventricular tachycardia; TdP: torsade de pointes; SCD: sudden cardiac death.

Duration of the prospective studies was mostly 6 months to 2 years where as one of the retrospective study reviewed a database for 33 years. Remaining retrospective study usually lasted from 1 to 5 years. The setting in which patients were studies either inpatient or outpatient except for one study where the setting was ICU and emergency room. QTc interval was measured predominantly by Bazett's formula except for few using Fridericia's formula. QTc interval was measured using routine 12-lead EKG in all the studies.

Changes in QTc were discussed only in 11 studies. QTc decreased in risperidone group in a large study of 1,362 patients compared to haloperidol \[[@R31]\]. Same effect with use of risperidone was seen in a study comparing the drug against olanzapine \[[@R25]\]. But the results are not consistent with another two studies where risperidone compared to olanzapine and aripiprazole had prolonged QTc compared to the latter drugs \[[@R24], [@R26]\]. In a study of patients with methadone, QTc was prolonged nearly by 66 ms \[[@R13]\]. Van der sijs et al studied use of multiple drugs (haloperidol, amiodarone, sotalol), QTc prolongation was found to be 59.76 ms \[[@R18]\].

Discussion {#s4}
==========

Drug-induced Long QT syndrome holds an undesirable risk of arrhythmias and SCD causing substantial concern to clinicians. Although more than 150 drugs have already been implicated ([www.qtdrugs.org](http://www.qtdrugs.org)), more are continuously being identified by the Food and Drug Administration (FDA). This has led to the withdrawal of many newly developing, otherwise useful drugs after noticing a small number of cases with QT prolongation and arrhythmias in phase 2 and 3 stages of drug trials. Drugs that have been taken off the market in the United States and other countries because of their increased risk of TdP are namely, ondansetron, cisapride, terfenadine, astemizole.

In our qualitative approach, methadone was reported in four studies and found to have highest proportion of patients with QTc prolongation and TdP in single study. Cumulatively, concomitant use of multiple QT prolonging drugs is found to have largest patient population with significant QTc prolongation. Use of multiple QT prolonging drugs was studied most commonly followed by use of drugs such as haloperidol, risperidone and aripiprazole individually. Schizophrenia is the most common diagnosis in which outcomes of QT prolongation was evaluated. Usage of multiple QT prolonging drugs and sertindole is associated with SCD. Researches which studied azithromycin, methadone and sertindole, multiple QT prolonging drugs were found to have reported all-cause mortality. Amiodarone, sotalol and dofetilide are notorious for significant QTc prolongation and especially the risk of ventricular arrhythmias TdP is higher. Most commonly studied non-cardiac drugs are antipsychotics like haloperidol, risperidone, olanzapine and aripiprazole. QTc prolongation doesn't correspond to ventricular arrhythmias or TdP in non-cardiac drugs.

On a study of 172 patients, the most common cause for QTc prolongation was QTc interval-prolonging medication and was deemed most responsible in 48% of patients, with 25% of these patients taking ≥ two offending drugs \[[@R39]\]. Out of seven patients who died with VF, cause of death was myocardial ischemia in three patients and severe heart failure in three patients and one had VF during seizure. Antidepressants caused QTc prolongation in 53 patients and amiodarone in 36 patients \[[@R39]\].

TdP was reported in less than 1% with use of amiodarone though it is one of the most common QTc prolonging cardiac drugs \[[@R40]\]. There were no significant differences in mean QTc interval duration in users of citalopram and paroxetine and their corresponding reference patients according to study by Van Haelst et al. The use of an SSRI by elderly surgical patients was not associated with the occurrence of QT interval prolongation \[[@R36]\]. Hasnain et al in their comprehensive review reported 28 cases of TdP, six (21.4 %) experienced it with QTc interval \< 500 ms; 75 % of TdP cases occurred at therapeutic doses \[[@R41]\].

Acquired QTc interval prolongation is more common than congenital and is typically ascribed to drugs that incidentally block the IKr current or systemic illness that indirectly prolongs the QTc interval through ill-defined mechanisms. Drugs block the delayed rectifier potassium channel which is coded by human ether-a-go-go-related gene (hERG). The distinct molecular structure of hERG channel makes it more susceptible to medications. IKr current plays an important role in phase 3 of ventricular action potential (ventricular repolarization) \[[@R42]\]. Prolongation of ventricular action potential due to blockage of delayed rectifier potassium channel leads to fluctuation in membrane potential leading to development of early after depolarization (EAD). After reaching a certain threshold with wider heterogeneity, EADs can lead to reentrant excitation and TdP which can result in SCD \[[@R43]\].

Strengths and limitations {#s4a}
-------------------------

There is significant number of randomized control trials which increases the strength of this systematic review. Baseline QTc and measured QTc after the use of specific QT prolonging drug was either not reported or discussed in a large number of studies. There is an inconsistency in measuring the risk of QTc prolongation in most of the studies. There are also unclear reports of ventricular arrhythmias or TdP studied in the included articles.

Conclusions {#s4b}
-----------

Acquired QTc prolongation due to drugs is the most common cause for QTc prolongation observed in clinical practice. Caution should be exercised in case of usage of cardiac drugs like amiodarone, sotalol and dofetilide as they are increasingly associated with fatal arrhythmias. Though antipsychotics and antibiotics could cause significant QTc prolongation, ventricular tachycardia or TdP is more common with simultaneous use of two or more other QT prolonging drugs. More detailed randomized controlled studies with accurate description of baseline QTc, change in QTc interval and appropriate report of any significant ventricular arrhythmias with usage of multiple QTc prolonging drugs should be performed in future.
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